PrascendPrascend (Pergolide) Tablets for Horses 1 mg - 60 or 160 Count
Description: PRASCEND (pergolide tablets) is the #1 treatment approved by the FDA for Pituitary Pars Intermedia Dysfunction (PPID).4Proven to improve clinical signs such as delayed shedding, muscle wasting, and abnormal sweating. PRASCEND helps horses with PPID have healthier, more comfortable lives. PRASCEND is a rectangular light red colored, half-scored tablet containing 1 mg pergolide, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only.1 Only treatment for PPID (equine Cushing's disease) in horses approved by the FDA1 Improves clinical signs within 3 months, sustained through 6 months1 3 out of 4 horses considered treatment successes in clinical trials1 Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months1 Incorporating PRASCEND tablets into a PPID management protocol has been shown to reduce clinical signs of the disease and enhance horses' overall quality of life. Clinical research and real-world evidence show that horses treated with PRASCEND: Are supported with the only therapy for PPID approved by the FDA1 Showed improved clinical signs within 3 months, with continued improvement at 6 months1 Experienced significant improvement in delayed shedding (89%), muscle wasting, abnormal fat distribution, and abnormal sweating within 6 months1 Achieved a 76.1% overall treatment success rate based on clinical signs and endocrine testing Sustained improvement and owner satisfaction in a long-term study, with 87% of owners reporting they would choose PRASCEND again for another PPID horse2 Benefit from consistent, reliable dosing and potency, unlike compounded pergolide products, which have been shown to lose effectiveness rapidly3 References: 1. Boehringer Ingelheim Vetmedica, Inc.PRASCEND (pergolide mesylate) Tablets for Horses: Freedom of Information Summary. NADA 141-331. US Food and Drug Administration. Sept 7, 2011. 2. Schott HC, Strachota JR, Marteniuk JV, Refsal KR. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide.J Vet Intern Med.2025;39:e70109. doi:10.1111 jvim.70109 3. Stanley SD, DiMaio Knych H. Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate. In:Proc 56th Annu Conv Am Assoc Equine Pract.2010:274-276. 4. Boehringer Ingelheim. Data Supporting PRASCEND as #1 treatment for PPID. Supporting Document VV-55869. November 2025. Product sourced directly from the manufacturer or their approved distributor. Guaranteed genuine product backed by the manufacturer. For: Horses Brand Name: Prascend Drug Class: Dopamine receptor agonist Product Strength & Size: Prascend Tablets contain 1 mg of pergolide in eachtablet- packaged 10 tablets per blister and 60 or 160 tablets per carton. Please ensure the selected product and package size are appropriate for your pet, as recommended by your veterinarian. For current availability, please refer to the product selection above. Manufacturer: Boehringer Ingelheim Active Ingredients: Pergolide mesylate Inactive Ingredients: Complete inactive ingredients list not provided by manufacturer. Usage: For additional product information, please refer to the product label and the full Prescribing Information provided in the manufacturer's package insert. Prascend Tablets should be given orally as directed by your veterinarian. Please consult your veterinarian before making any changes or discontinuing the prescribed dosing schedule. Manufacturer Dosage and Administration: Administer PRASCEND (pergolide tablets) orally at a starting dose of 2 mcg kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg kg daily. The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment. DOSING TABLEBody Weight2 mcg kg Dosage4 mcg kg Dosage130-340 kg (300-749 lb)0.5 tablet1 tablet341-567 kg (750-1,249 lb)1 tablet2 tablets568-795 kg (1,250-1,749 lb)1.5 tablets3 tablets796-1,022 kg (1,750-2,249 lb)2 tablets4 tablets Missed Doses: Administer the dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not give more medication than prescribed or two doses at once. If you have questions about your pet's prescribed dosing schedule (e.g., timing, interval), please consult your veterinarian. Side Effects: For complete product information, including potential side effects, please refer to the manufacturer's package insert. As with all drugs, side effects may occur; the most common side effect of this medication is decreased appetite, which is typically mild. If severe, your veterinarian may recommend a temporary dose adjustment. Contact your veterinarian immediately if colic, laminitis, lameness, or fainting collapse occurs. Notify your veterinarian if your horse experiences any of the effects described above, or if you notice any other side effects that are persistent or troublesome. If you notice anything unusual, please consult your veterinarian. Precautions: Before using this product, please review the product label and package insert for important safety information, including any relevant warnings and precautions. For oral use in horses only. Not for use in humans. Not for use in horses intended for human consumption. Pregnant or lactating women should wear gloves when administering this product. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. The use of PRASCEND in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation. Do not administer this medication to horses with a known or suspected allergy hypersensitivity to any ergot derivative, including pergolide mesylate, or any of its ingredients. Allergic reactions to medications may occur. Please inform Vetsource and your veterinarian if your pet has any known sensitivities or allergies, especially to medications and supplements. If your pet displays symptoms of an allergic reaction, discontinue therapy and call your veterinarian immediately or seek emergency veterinary attention. Symptoms may include (but are not limitedto): swollen lips, tongue, face, or airways; difficulty breathing; agitation; profuse salivation; and widespread hives or itching. Drug & Food Interactions: PRASCEND is approximately 90% associated with plasma proteins. Use caution if administering PRASCEND with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with PRASCEND (a dopamine agonist) since these agents may diminish the effectiveness of PRASCEND tablets. *NOTE: this may not be a comprehensive list. As with all medications, please consult your veterinarian if you have any questions or concerns prior to use. Contact your veterinarian if your pet experiences any unusual reactions when multiple medications and or supplements are given together. Please ensure your veterinarian is aware of all medications, supplements, and over-the-counter (OTC) products that your pet is currentView details
